Business Update17 May 2024, 01:52 pm
Zydus Lifesciences and MSN Announce Exclusive Licensing and Supply Agreement for Cabozantinib Tablets in the US Market
AI Summary
Zydus Lifesciences and MSN have entered into an exclusive licensing and supply agreement for Cabozantinib Tablets, a generic version of CABOMETYX, in the US market. MSN will be responsible for manufacturing and supplying the product upon regulatory approval, while Zydus will market, distribute, and sell it. MSN may be eligible for 180 days of generic drug exclusivity. The total addressable market opportunity is approximately US$ 1,464 million.
Key Highlights
- Exclusive licensing and supply agreement signed between Zydus and MSN
- MSN will manufacture and supply Cabozantinib Tablets upon regulatory approval
- Zydus to market, distribute, and sell the product in the US market
- MSN may be eligible for 180 days of generic drug exclusivity
- Total addressable market opportunity is approximately US$ 1,464 million